Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Antibodies and Vaccines as Drugs for COVID-19 (2021EK31)
Antibodies as Drugs: From B Cell Biology to New Treatments (2020B1)
Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (2017A7)
Antibodies as Drugs (2016X2)
Antibodies as Drugs: Immunological Scaffolds as Therapeutics (2015J8)
Prophylactic and Therapeutic Antibodies (2014Q3)
Antibodies as Drugs (2013J3)

Web Desc
Antibodies as Drugs Organizer(s): Nils Lonberg, Stephen M. Ansell and Edith Perez Date: February 06 - 11, 2011 Location: Keystone Resort, Keystone, CO, USA Sponsored by Bristol-Myers Squibb Company, Novo Nordisk A/S and Takeda Pharmaceutical Company Limited Summary of Meeting: The therapeutic antibody field has matured to the point where antibody based therapies have become commonly prescribed for many diseases, particularly in cancer and rheumatology. This conference will bring together basic scientists, translational clinicians, and pharmaceutical industry scientists engaged in antibody drug discovery and development. Interactive discussions of current state of the art and areas for future work in this field will provide the structure for this meeting. Scholarship Deadline: October 6 2010 Discounted Abstract Deadline: October 6 2010 Abstract Deadline: November 8 2010 Discounted Registration Deadline: December 6 2010 We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Abbott Laboratories Alder Biopharmaceuticals, Inc. Bristol-Myers Squibb Company Genentech, Inc. Genmab B.V. ImmunoGen, Inc. MedImmune Micromet, Inc. Seattle Genetics, Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Antibodies as Drugs

Organizer(s): Nils Lonberg, Stephen M. Ansell and Edith Perez

Date: February 06 - 11, 2011
Location: Keystone Resort, Keystone, CO, USA

Sponsored by Bristol-Myers Squibb Company, Novo Nordisk A/S and Takeda Pharmaceutical Company Limited

Summary of Meeting:

The therapeutic antibody field has matured to the point where antibody based therapies have become commonly prescribed for many diseases, particularly in cancer and rheumatology. This conference will bring together basic scientists, translational clinicians, and pharmaceutical industry scientists engaged in antibody drug discovery and development. Interactive discussions of current state of the art and areas for future work in this field will provide the structure for this meeting.

Scholarship Deadline: October 6 2010

Discounted Abstract Deadline: October 6 2010

Abstract Deadline: November 8 2010

Discounted Registration Deadline: December 6 2010

We gratefully acknowledge additional support for this conference from:

Boehringer Ingelheim Pharmaceuticals, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Abbott Laboratories

Alder Biopharmaceuticals, Inc.

Bristol-Myers Squibb Company

Genentech, Inc.

Genmab B.V.

ImmunoGen, Inc.

MedImmune

Micromet, Inc.

Seattle Genetics, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, February 06 \| 3:00PM - 7:30PM Registration Room: Longs Peak Foyer
Sunday, February 06 \| 5:00PM - 5:00PM SuperBowl shown on the big screen with cash bar service avai lable. Room: Longs/Grays Peak
Sunday, February 06 \| 6:15PM - 7:15PM Refreshments Room: Longs Peak Foyer
Sunday, February 06 \| 7:15PM - 8:30PM Welcome and Keynote Address Room: Longs/Grays Peak Speaker 1 of 1 Mark X. Sliwkowski, Genentech, Inc., USA Multiple Approaches to Targeting ErbB/HER Receptors in Solid Tumors
Monday, February 07 \| 7:00AM - 8:00AM Breakfast Room: Quandary Peak
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 1 of 8 * Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 2 of 8 Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany Bispecific Antibodies Designed for Polyclonal T Cell Engagement
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 3 of 8 Ian M. Tomlinson, GlaxoSmithKline, UK Domain Antibodies for Human Therapy
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 4 of 8 Jeffrey V. Ravetch, Rockefeller University, USA Hypersialylated Antibodies and Antibody Fragments for Immunomodulation
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 5 of 8 George J. Weiner, University of Iowa, USA CDC and ADCC: Synergistic or Antagonistic Mechanisms?
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 6 of 8 Adrian Wiestner, NHLBI, National Institutes of Health, USA Short Talk: Targeting the Fcmu-receptor: mAbs and Fc-Derived Protein Scaffolds Offer Complementary Approaches for Cancer Therapy
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 7 of 8 Philip D. Bardwell, AbbVie Bioresearch Center, USA Short Talk: Re-Targeting Effector T Cells to Tumor Cell Targets using Dual Variable Domain-Immunoglobulins (DVD-IgTM)
Monday, February 07 \| 8:00AM - 11:30AM New Antibody Platform Technologies I: Fc Modifications, Bisp ecifics, and Fragments Room: Longs/Grays Peak Speaker 8 of 8 Margaret E. Ackerman, Dartmouth College, USA Short Talk: Tuning the Antibody Response: Natural Modulation of Antibody Glycosylation and Effector Function in HIV Infection
Monday, February 07 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Monday, February 07 \| 11:30AM - 1:00PM Poster Setup Room: Quandary Peak
Monday, February 07 \| 11:30AM - 11:30AM On Own for Lunch and Recreation
Monday, February 07 \| 1:00PM - 10:00PM Poster Viewing Room: Quandary Peak
Monday, February 07 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Monday, February 07 \| 5:00PM - 7:00PM New Antibody Platform Technologies II: Payloads Room: Longs/Grays Peak Speaker 1 of 5 * Mark X. Sliwkowski, Genentech, Inc., USA
Monday, February 07 \| 5:00PM - 7:00PM New Antibody Platform Technologies II: Payloads Room: Longs/Grays Peak Speaker 2 of 5 Nils Lonberg, Canaan Partners, USA Alkylating Agent Drug Conjugates
Monday, February 07 \| 5:00PM - 7:00PM New Antibody Platform Technologies II: Payloads Room: Longs/Grays Peak Speaker 3 of 5 John M. Lambert, USA Maytansinoids as Payloads for ADCs: Effective Drug Products for Treating Cancer
Monday, February 07 \| 5:00PM - 7:00PM New Antibody Platform Technologies II: Payloads Room: Longs/Grays Peak Speaker 4 of 5 Peter D. Senter, Seattle Genetics Inc., USA Empowered Antibodies for Cancer Therapy
Monday, February 07 \| 5:00PM - 7:00PM New Antibody Platform Technologies II: Payloads Room: Longs/Grays Peak Speaker 5 of 5 Christoph Rader, The Scripps Research Institute, USA Short Talk: A Sequential Program and Arm Strategy for Fc Fragments with a C-Terminal Selenocysteine
Monday, February 07 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Quandary Peak
Monday, February 07 \| 7:30PM - 10:00PM Poster Session 1 Room: Quandary Peak
Tuesday, February 08 \| 7:00AM - 8:00AM Breakfast Room: Quandary Peak
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 1 of 6 * Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 2 of 6 Ian A. Wilson, The Scripps Research Institute, USA Antibody Recognition of HIV-1 and Influenza
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 3 of 6 Don M. Benson, Ohio State University Comprehensive Cancer Center, USA A Role for PD-1 in NK Cell Immunity Against Multiple Myeloma
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 4 of 6 James E. Crowe, Jr., Vanderbilt University Medical Center, USA Naturally Occurring Human Antibody Responses to Viral Infections
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 5 of 6 Alan J. Korman, Vir Biotechnology, Inc., USA Lag-3 Targeted Immunotherapy
Tuesday, February 08 \| 8:00AM - 11:15AM Immune Modulation I: Infectious Disease and Cancer Room: Longs/Grays Peak Speaker 6 of 6 Gary J. Nabel, Sanofi, USA Identification of Broadly Neutralizing Human MAbs to HIV-1: Applications to Vaccine Design, Passive Protection and HIV Therapy
Tuesday, February 08 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Tuesday, February 08 \| 11:15AM - 1:00PM Poster Setup Room: Quandary Peak
Tuesday, February 08 \| 11:15AM - 11:15AM On Own for Lunch and Recreation
Tuesday, February 08 \| 1:00PM - 10:00PM Poster Viewing Room: Quandary Peak
Tuesday, February 08 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Tuesday, February 08 \| 5:00PM - 7:00PM Immune Modulation II: Cancer Room: Longs/Grays Peak Speaker 1 of 5 * Alan J. Korman, Vir Biotechnology, Inc., USA
Tuesday, February 08 \| 5:00PM - 7:00PM Immune Modulation II: Cancer Room: Longs/Grays Peak Speaker 2 of 5 Kevin Heller, Bristol-Myers Squibb Company, USA CTLA-4 Blockade for Cancer Immunotherapy
Tuesday, February 08 \| 5:00PM - 7:00PM Immune Modulation II: Cancer Room: Longs/Grays Peak Speaker 3 of 5 Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA B7-H1/PD-1 Blockade for Cancer Immunotherapy
Tuesday, February 08 \| 5:00PM - 7:00PM Immune Modulation II: Cancer Room: Longs/Grays Peak Speaker 4 of 5 Paul M. Sondel, University of Wisconsin-Madison, USA Cell-Mediated Destruction of Neuroblastoma and Melanoma Facilitated by Anti-GD2 Reagents ch14.18 and hu14.18-IL2
Tuesday, February 08 \| 5:00PM - 7:00PM Immune Modulation II: Cancer Room: Longs/Grays Peak Speaker 5 of 5 Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA Short Talk: Reshaping CD4 and CD8 Memory T Cell Proliferation by Treating Cancer Patients with an Anti-OX40 Ab: Immunologic and Clinical Assessment of a Phase I Trial
Tuesday, February 08 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Quandary Peak
Tuesday, February 08 \| 7:30PM - 10:00PM Poster Session 2 Room: Quandary Peak
Wednesday, February 09 \| 7:00AM - 8:00AM Breakfast Room: Quandary Peak
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 1 of 8 * Stephen M. Ansell, Mayo Clinic, USA
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 2 of 8 Trudi M. Veldman, AbbVie, Inc., USA Modulation of the IL-1 Axis for RA and OA using DVD-IgTM Technology
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 3 of 8 Barbara White, Corbus Pharmaceuticals, USA Blocking Type I Interferons in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 4 of 8 Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia Combination Chemo-Immunotherapy
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 5 of 8 Drew M. Pardoll, Johns Hopkins University School of Medicine, USA Checkpoint Blockade Combination Therapies
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 6 of 8 Eric Dobrzynski, GlaxoSmithKline, USA Short Talk: PanELR: A High Affinity Neutralizing Monoclonal Antibody Targeting Multiple Human Pro-Inflammatory ELRCXC Chemokines
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 7 of 8 Stephen A. Beers, University of Southampton, UK Short Talk: Re-Programming Macrophages to Enhance Antibody Immunotherapy
Wednesday, February 09 \| 8:00AM - 11:30AM Immune Modulation III: Inflammatory Disease and Cancer Room: Longs/Grays Peak Speaker 8 of 8 Joe Ponte, Tolerx, Inc., USA Short Talk: In vitro and in vivo Characterization of TRX518, a Novel Anti-huGITR Monoclonal Antibody and New Phase 1 Clinical Trial Candidate
Wednesday, February 09 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Wednesday, February 09 \| 11:30AM - 11:30AM On Own for Lunch and Recreation
Wednesday, February 09 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Wednesday, February 09 \| 5:00PM - 7:00PM Cancer I Room: Longs/Grays Peak Speaker 1 of 5 * Ronald P. Taylor, University of Virginia School of Medicine, USA
Wednesday, February 09 \| 5:00PM - 7:00PM Cancer I Room: Longs/Grays Peak Speaker 2 of 5 Stephen M. Ansell, Mayo Clinic, USA Therapeutic Antibody Combinations in the Treatment of Lymphoproliferative Disorders
Wednesday, February 09 \| 5:00PM - 7:00PM Cancer I Room: Longs/Grays Peak Speaker 3 of 5 Ronald Levy, Stanford University, USA Combination Therapy to Enhance Antibody ADCC Activity: CD137 MAbs as an Activator of NK Cell Function
Wednesday, February 09 \| 5:00PM - 7:00PM Cancer I Room: Longs/Grays Peak Speaker 4 of 5 Paul W. H. I. Parren, Leiden University Medical Center, Netherlands CD38 as a Target for MM
Wednesday, February 09 \| 5:00PM - 7:00PM Cancer I Room: Longs/Grays Peak Speaker 5 of 5 Waleed Alduaij, University of Manchester, Paterson Institute of Cancer Research, UK Short Talk: Novel Type II Anti-CD20 Monoclonal Antibody (GA101) Evokes Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Malignancies
Wednesday, February 09 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Quandary Peak
Thursday, February 10 \| 7:00AM - 8:00AM Breakfast Room: Quandary Peak
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 1 of 7 * Nils Lonberg, Canaan Partners, USA
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 2 of 7 Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands Effective Functions of CD20 Antibodies
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 3 of 7 Georgiana K. Ellis, Seattle Cancer Care Alliance, USA Cancer, Bone Health and Denosumab
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 4 of 7 Eric L. Sievers, Seattle Genetics, Inc., USA Empowered Antibodies for Cancer Therapy: The Case of Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 5 of 7 Wayne Chu, Genentech, Inc., USA Trastuzumab-DM1 (T-DM1) Antibody-Drug Conjugate (ADC): Optimizing HER2-Targeted Cancer Therapy
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 6 of 7 Aaron K. Sato, Twist Bioscience, USA Short Talk: Wnt Pathway Inhibition Decreases Tumorigenicity and Promotes Differentiation of Human Tumors
Thursday, February 10 \| 8:00AM - 11:15AM Cancer II Room: Longs/Grays Peak Speaker 7 of 7 Helle Jane Jacobsen, Symphogen A/S, Denmark Short Talk: Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Thursday, February 10 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Thursday, February 10 \| 11:15AM - 11:15AM On Own for Lunch and Recreation
Thursday, February 10 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Thursday, February 10 \| 5:00PM - 7:00PM Cancer III Room: Longs/Grays Peak Speaker 1 of 5 * Ronald Levy, Stanford University, USA
Thursday, February 10 \| 5:00PM - 7:00PM Cancer III Room: Longs/Grays Peak Speaker 2 of 5 Ronald P. Taylor, University of Virginia School of Medicine, USA Antigen Shaving as a Mechanism of Resistance to Antibody Therapy
Thursday, February 10 \| 5:00PM - 7:00PM Cancer III Room: Longs/Grays Peak Speaker 3 of 5 Roy S. Herbst, University of Texas MD Anderson Cancer Center, USA Antibodies Targeting Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer
Thursday, February 10 \| 5:00PM - 7:00PM Cancer III Room: Longs/Grays Peak Speaker 4 of 5 John A. Latham, Alder BioPharmaceuticals, USA Therapeutic Intervention in IL-6-Driven Disease: Clinical Experience with ALD518
Thursday, February 10 \| 5:00PM - 7:00PM Cancer III Room: Longs/Grays Peak Speaker 5 of 5 Mark S. Cragg, University of Southampton, UK Short Talk: Controlling Antigenic Modulation - Key Role of FcgammaRIIb in Regulating the Response to Rituximab
Thursday, February 10 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Quandary Peak
Thursday, February 10 \| 8:00PM - 11:00PM Entertainment Room: Quandary Peak
Thursday, February 10 \| 8:00PM - 11:00PM Cash Bar Room: Quandary Peak
Friday, February 11 \| 10:25AM - 10:25AM Departure *Session Chair.